Adverse Drug Events
Cross-source consensus on Adverse Drug Events from 1 sources and 5 claims.
1 sources · 5 claims
Risks & contraindications
Evidence quality
Highlighted claims
- In a USA latent tuberculosis treatment study, 13.4% of incarcerated patients receiving rifampicin and pyrazinamide experienced adverse drug events, mainly hepatotoxicity. — Exploring medication safety in prisons: a scoping review
- In a Taiwan prison isoniazid study, 12% of inmates had adverse events causing treatment discontinuation, with hepatotoxicity most common. — Exploring medication safety in prisons: a scoping review
- Adverse drug events were examined in three included studies, making them less commonly studied than non-adherence or PIP/PIMs. — Exploring medication safety in prisons: a scoping review
- Older age, abnormal baseline aspartate aminotransferase, and excess alcohol use were associated with hepatotoxicity in latent tuberculosis treatment. — Exploring medication safety in prisons: a scoping review
- Hepatitis C virus infection was identified as an independent risk factor for adverse drug events in high-hepatitis-prevalence populations. — Exploring medication safety in prisons: a scoping review